{"log_id": 1348915429050426781, "direction": 0, "words_result_num": 41, "words_result": [{"probability": {"variance": 0.067456, "average": 0.731374, "min": 0.471651}, "location": {"width": 36, "top": 167, "height": 25, "left": 1144}, "words": "式食"}, {"probability": {"variance": 0, "average": 0.999997, "min": 0.999997}, "location": {"width": 28, "top": 204, "height": 27, "left": 1143}, "words": "药"}, {"probability": {"variance": 2.3e-05, "average": 0.997585, "min": 0.972844}, "location": {"width": 746, "top": 249, "height": 36, "left": 272}, "words": "尚无托珠单抗在孕妇中应用的足够资料。一项在猴中进行的实验显示,其无潜在致畸"}, {"probability": {"variance": 0, "average": 0.961522, "min": 0.961522}, "location": {"width": 24, "top": 242, "height": 27, "left": 1157}, "words": "附"}, {"probability": {"variance": 1.9e-05, "average": 0.997436, "min": 0.976383}, "location": {"width": 785, "top": 289, "height": 37, "left": 232}, "words": "作用,但在大剂量使用时可增加自然流产死胎的危险(见【药理毒理】其它部分)。有关"}, {"probability": {"variance": 1.7e-05, "average": 0.998407, "min": 0.980304}, "location": {"width": 787, "top": 330, "height": 36, "left": 231}, "words": "人类的相关性数据不详。在治疗过程中以及治疗后3个月内,有怀孕可能性的女性必须采"}, {"probability": {"variance": 6e-06, "average": 0.997896, "min": 0.992383}, "location": {"width": 164, "top": 378, "height": 26, "left": 233}, "words": "取有效的避孕措施"}, {"probability": {"variance": 1.3e-05, "average": 0.998326, "min": 0.982185}, "location": {"width": 461, "top": 413, "height": 30, "left": 272}, "words": "除非有明确的医学需要,在孕妇中不应使用托珠单抗"}, {"probability": {"variance": 5e-06, "average": 0.998289, "min": 0.988977}, "location": {"width": 745, "top": 447, "height": 36, "left": 275}, "words": "尚不清楚托珠单抗是否通过乳汁分泌。虽然可以在母乳中检测到用同位素标记的内源"}, {"probability": {"variance": 1e-05, "average": 0.997872, "min": 0.987561}, "location": {"width": 788, "top": 486, "height": 37, "left": 233}, "words": "性免疫球蛋白,但是由于托珠单抗在消化系统中快速降解,所以托珠单抗不太可能通过哺"}, {"probability": {"variance": 0.003421, "average": 0.98596, "min": 0.637553}, "location": {"width": 788, "top": 524, "height": 37, "left": 233}, "words": "乳被吸收。判断是否继续终止哺乳或是继续/终止托珠单抗治疗,需要权衡母乳喂养对婴"}, {"probability": {"variance": 1.6e-05, "average": 0.998021, "min": 0.98275}, "location": {"width": 365, "top": 571, "height": 27, "left": 235}, "words": "儿及托珠单抗治疗对哺乳妇女之间的利弊"}, {"probability": {"variance": 7e-06, "average": 0.998114, "min": 0.9925}, "location": {"width": 111, "top": 612, "height": 25, "left": 243}, "words": "【儿童用药】"}, {"probability": {"variance": 0.000214, "average": 0.995071, "min": 0.925256}, "location": {"width": 744, "top": 643, "height": 35, "left": 277}, "words": "托珠单抗用于除患有全身型幼年特发性关节炎(sJA)以外疾病患儿的疗效和安全性"}, {"probability": {"variance": 0.000122, "average": 0.996373, "min": 0.949832}, "location": {"width": 380, "top": 687, "height": 31, "left": 236}, "words": "尚未确定。尚未在2岁以下儿童中进行研究"}, {"probability": {"variance": 2e-06, "average": 0.998657, "min": 0.995344}, "location": {"width": 115, "top": 731, "height": 25, "left": 243}, "words": "【老年用药】"}, {"probability": {"variance": 0.013068, "average": 0.968926, "min": 0.421504}, "location": {"width": 745, "top": 760, "height": 36, "left": 278}, "words": "在临床研究1V中接受托珠单抗治疗的2644例患者中,共有435例类风湿关节炎患"}, {"probability": {"variance": 1.3e-05, "average": 0.997944, "min": 0.97933}, "location": {"width": 785, "top": 799, "height": 36, "left": 239}, "words": "者年龄在65岁及以上,包括50例年龄在75岁及以上的患者。使用托珠单抗的严重感染"}, {"probability": {"variance": 0.0003, "average": 0.996169, "min": 0.888539}, "location": {"width": 785, "top": 838, "height": 37, "left": 239}, "words": "率在65岁及以上的患者高于年龄低于65岁的患者。由于老年人群的感染率一般较高,给"}, {"probability": {"variance": 0.008686, "average": 0.964337, "min": 0.701158}, "location": {"width": 185, "top": 885, "height": 27, "left": 239}, "words": "老年人治疗时应慎重"}, {"probability": {"variance": 1e-06, "average": 0.99907, "min": 0.996809}, "location": {"width": 152, "top": 926, "height": 25, "left": 247}, "words": "【药物相互作用】"}, {"probability": {"variance": 0.006871, "average": 0.980437, "min": 0.480774}, "location": {"width": 746, "top": 958, "height": 34, "left": 281}, "words": "体外试验数据表明,Ⅱ6可降低多种细胞色素P450(CYP450)同工酶(包括"}, {"probability": {"variance": 0.001056, "average": 0.988351, "min": 0.768656}, "location": {"width": 789, "top": 995, "height": 37, "left": 241}, "words": "CYP1A2、CYP2B6、CYP2C9、CYP2C19、CYP2D6和GYP3A4)的mRNA表达水平"}, {"probability": {"variance": 1.7e-05, "average": 0.997765, "min": 0.97634}, "location": {"width": 786, "top": 1035, "height": 36, "left": 242}, "words": "通过与临床相关浓度的托珠单抗共同培养可逆转这种表达水平的下降。相应地,使用托珠"}, {"probability": {"variance": 0.000319, "average": 0.994062, "min": 0.884521}, "location": {"width": 787, "top": 1074, "height": 37, "left": 242}, "words": "单抗治疗的RA患者可抑制儿6信号传导,使CYP450活性恢复至较高水平,高于不使用"}, {"probability": {"variance": 0.000347, "average": 0.990581, "min": 0.918525}, "location": {"width": 787, "top": 1113, "height": 37, "left": 242}, "words": "托珠单抗治疗的患者,结果导致CYP450底物药物的代谢增加。托珠单抗对CYP2C8或"}, {"probability": {"variance": 1.5e-05, "average": 0.997657, "min": 0.982177}, "location": {"width": 785, "top": 1153, "height": 36, "left": 245}, "words": "转运蛋白(如P糖蛋白(Pgp))的作用未知。这对治疗指数窄、需进行个体化剂量调整"}, {"probability": {"variance": 3e-05, "average": 0.997061, "min": 0.970259}, "location": {"width": 785, "top": 1192, "height": 36, "left": 245}, "words": "的CYP450底物可能有临床相关性。使用这类药物治疗的患者在开始托珠单抗治疗时,应"}, {"probability": {"variance": 0.002309, "average": 0.988073, "min": 0.694066}, "location": {"width": 786, "top": 1230, "height": 39, "left": 246}, "words": "对其药效(如华法林)或药物浓度(环孢素或茶碱)进行治疗监测,需要时对这类药物进"}, {"probability": {"variance": 0.004116, "average": 0.985245, "min": 0.585159}, "location": {"width": 798, "top": 1270, "height": 38, "left": 247}, "words": "行个体化剂量调整。当托珠单抗与不能降低疗效的药物(如口服避孕药(CYP3A4底物))"}, {"probability": {"variance": 0.016323, "average": 0.94878, "min": 0.610815}, "location": {"width": 164, "top": 1318, "height": 26, "left": 247}, "words": "合并用药吋应慎重"}, {"probability": {"variance": 0, "average": 0.999452, "min": 0.999272}, "location": {"width": 81, "top": 1357, "height": 24, "left": 289}, "words": "辛伐他汀"}, {"probability": {"variance": 0.000554, "average": 0.974023, "min": 0.950481}, "location": {"width": 113, "top": 1347, "height": 48, "left": 766}, "words": "股份"}, {"probability": {"variance": 0.003311, "average": 0.982137, "min": 0.697147}, "location": {"width": 745, "top": 1387, "height": 37, "left": 289}, "words": "辛伐他汀是GYP3A4和有机阴离子转运蛋白(OATP1B1)底物。未使用托珠单抗治"}, {"probability": {"variance": 1.6e-05, "average": 0.996972, "min": 0.980024}, "location": {"width": 788, "top": 1426, "height": 39, "left": 247}, "words": "疗的12例RA患者接受辛伐他汀40mg,其辛伐他汀及其代谢物(辛伐他汀酸)的暴露比"}, {"probability": {"variance": 0.00396, "average": 0.984382, "min": 0.593942}, "location": {"width": 764, "top": 1467, "height": 37, "left": 249}, "words": "健康受试者分别高4~10倍和2倍。单次输注托珠单抗(10mg/kg)后一周,辛伐他江"}, {"probability": {"variance": 0.048117, "average": 0.732295, "min": 0.512939}, "location": {"width": 96, "top": 1472, "height": 43, "left": 1015}, "words": "份香"}, {"probability": {"variance": 1.2e-05, "average": 0.998139, "min": 0.979244}, "location": {"width": 714, "top": 1507, "height": 36, "left": 249}, "words": "辛伐他汀酸的暴露分别下降57%和39%,达到类似于或略高于健康受试者的水平"}, {"probability": {"variance": 0, "average": 0.738554, "min": 0.738554}, "location": {"width": 38, "top": 1525, "height": 31, "left": 1116}, "words": "武"}, {"probability": {"variance": 0.00015, "average": 0.995827, "min": 0.945656}, "location": {"width": 707, "top": 1546, "height": 36, "left": 251}, "words": "者停止托珠单抗治疗后,辛伐他汀和辛伐他汀酸的暴露增加。在为RA患者选择"}, {"probability": {"variance": 0, "average": 0.998253, "min": 0.998253}, "location": {"width": 89, "top": 1540, "height": 69, "left": 1009}, "words": "★"}], "language": 3}